Asal Rahimi1, Kimberly Thomas2, Ann Spangler2, Roshni Rao3, Marilyn Leitch3, Rachel Wooldridge3, Aeisha Rivers3, Stephen Seiler4, Kevin Albuquerque2, Stella Stevenson2, Sally Goudreau4, Dan Garwood2, Barbara Haley5, David Euhus6, John Heinzerling7, Chuxiong Ding2, Ang Gao8, Chul Ahn8, Robert Timmerman2. 1. University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: asal.rahimi@utsouthwestern.edu. 2. University of Texas Southwestern Medical Center, Dallas, Texas. 3. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas. 5. Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. 6. Department of Surgery, Johns Hopkins University, Baltimore, Maryland. 7. Department of Radiation Oncology, Levine Cancer Institute, Charlotte, North Carolina. 8. Department of Statistics, University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract
PURPOSE: To evaluate the tolerability of a dose-escalated 5-fraction stereotactic body radiation therapy for partial-breast irradiation (S-PBI) in treating early-stage breast cancer after partial mastectomy; the primary objective was to escalate dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose. METHODS AND MATERIALS: Eligible patients included those with ductal carcinoma in situ or invasive nonlobular epithelial histologies and stage 0, I, or II, with tumor size <3 cm. Patients and physicians completed baseline and subsequent cosmesis outcome questionnaires. Starting dose was 30 Gy in 5 fractions and was escalated by 2.5 Gy total for each cohort to 40 Gy. RESULTS: In all, 75 patients were enrolled, with a median age of 62 years. Median follow-up for 5 cohorts was 49.9, 42.5, 25.7, 20.3, and 13.5 months, respectively. Only 3 grade 3 toxicities were experienced. There was 1 dose-limiting toxicity in the overall cohort. Ten patients experienced palpable fat necrosis (4 of which were symptomatic). Physicians scored cosmesis as excellent or good in 95.9%, 100%, 96.7%, and 100% at baseline and 6, 12, and 24 months after S-PBI, whereas patients scored the same periods as 86.5%, 97.1%, 95.1%, and 95.3%, respectively. The disagreement rates between MDs and patients during those periods were 9.4%, 2.9%, 1.6%, and 4.7%, respectively. There have been no recurrences or distant metastases. CONCLUSION: Dose was escalated to the target dose of 40 Gy in 5 fractions, with the occurrence of only 1 dose-limiting toxicity. Patients felt cosmetic results improved within the first year after surgery and stereotactic body radiation therapy. Our results show minimal toxicity with excellent cosmesis; however, further follow-up is warranted in future studies. This study is the first to show the safety, tolerability, feasibility, and cosmesis results of a 5-fraction dose-escalated S-PBI treatment for early-stage breast cancer in the adjuvant setting. Published by Elsevier Inc.
PURPOSE: To evaluate the tolerability of a dose-escalated 5-fraction stereotactic body radiation therapy for partial-breast irradiation (S-PBI) in treating early-stage breast cancer after partial mastectomy; the primary objective was to escalate dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose. METHODS AND MATERIALS: Eligible patients included those with ductal carcinoma in situ or invasive nonlobular epithelial histologies and stage 0, I, or II, with tumor size <3 cm. Patients and physicians completed baseline and subsequent cosmesis outcome questionnaires. Starting dose was 30 Gy in 5 fractions and was escalated by 2.5 Gy total for each cohort to 40 Gy. RESULTS: In all, 75 patients were enrolled, with a median age of 62 years. Median follow-up for 5 cohorts was 49.9, 42.5, 25.7, 20.3, and 13.5 months, respectively. Only 3 grade 3 toxicities were experienced. There was 1 dose-limiting toxicity in the overall cohort. Ten patients experienced palpable fat necrosis (4 of which were symptomatic). Physicians scored cosmesis as excellent or good in 95.9%, 100%, 96.7%, and 100% at baseline and 6, 12, and 24 months after S-PBI, whereas patients scored the same periods as 86.5%, 97.1%, 95.1%, and 95.3%, respectively. The disagreement rates between MDs and patients during those periods were 9.4%, 2.9%, 1.6%, and 4.7%, respectively. There have been no recurrences or distant metastases. CONCLUSION: Dose was escalated to the target dose of 40 Gy in 5 fractions, with the occurrence of only 1 dose-limiting toxicity. Patients felt cosmetic results improved within the first year after surgery and stereotactic body radiation therapy. Our results show minimal toxicity with excellent cosmesis; however, further follow-up is warranted in future studies. This study is the first to show the safety, tolerability, feasibility, and cosmesis results of a 5-fraction dose-escalated S-PBI treatment for early-stage breast cancer in the adjuvant setting. Published by Elsevier Inc.
Authors: Krishan R Jethwa; Sean S Park; Karthik Gonuguntla; Stephanie M Wick; Laura A Vallow; Christopher L Deufel; Thomas J Whitaker; Keith M Furutani; Kathryn J Ruddy; Kimberly S Corbin; Tina J Hieken; Robert W Mutter Journal: Int J Radiat Oncol Biol Phys Date: 2018-12-21 Impact factor: 7.038
Authors: Chirag Shah; Martin Keisch; Atif Khan; Douglas Arthur; David Wazer; Frank Vicini Journal: Ann Surg Oncol Date: 2021-01-13 Impact factor: 5.344
Authors: Daniela Alterio; Eliana La Rocca; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa; Stefania Volpe; Anna Maria Camarda; Alessia Casbarra; William Russell-Edu; Maria Alessia Zerella; Roberto Orecchia; Viviana Galimberti; Paolo Veronesi Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Rosie J Goodburn; Marielle E P Philippens; Thierry L Lefebvre; Aly Khalifa; Tom Bruijnen; Joshua N Freedman; David E J Waddington; Eyesha Younus; Eric Aliotta; Gabriele Meliadò; Teo Stanescu; Wajiha Bano; Ali Fatemi-Ardekani; Andreas Wetscherek; Uwe Oelfke; Nico van den Berg; Ralph P Mason; Petra J van Houdt; James M Balter; Oliver J Gurney-Champion Journal: Magn Reson Med Date: 2022-09-21 Impact factor: 3.737
Authors: Laura Lozza; Laura Fariselli; Marco Sandri; Mario Rampa; Valentina Pinzi; Maria Carmen De Santis; Marzia Franceschini; Giovanna Trecate; Ilaria Maugeri; Luisa Fumagalli; Francesca Bonfantini; Giulia Bianchi; Emanuele Pignoli; Elena De Martin; Roberto Agresti Journal: Radiat Oncol Date: 2018-03-23 Impact factor: 3.481
Authors: Todd A Aguilera; Eslam A Elghonaimy; Hussein Shehade; Marjan Rafat; Laura Castellini; Dadi Jiang; Mihalis Kariolis; Albert C Koong; Quynh-Thu Le; Lesley G Ellies; Erinn B Rankin; Edward E Graves; Amato J Giaccia Journal: Clin Cancer Res Date: 2020-02-25 Impact factor: 13.801
Authors: Jonathan W Lischalk; Hao Chen; Michael C Repka; Lloyd D Campbell; Olusola Obayomi-Davies; Shaan Kataria; Thomas P Kole; Sonali Rudra; Brian T Collins Journal: Adv Radiat Oncol Date: 2018-06-11
Authors: Won Hee Lee; Jee Suk Chang; Min Jung Kim; Vivian Youngjean Park; Jung Hyun Yoon; Se Young Kim; Jee Ye Kim; Hyung Seok Park; Seung Il Kim; Young Up Cho; Byeong Woo Park; Yong Bae Kim Journal: Front Oncol Date: 2020-04-29 Impact factor: 6.244